GA
SGNT

Geneva Advisors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Geneva Advisors’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-22,261
Closed -$518K – 719
2015
Q1 		$518K Hold
22,261
– – 0.01% 410
2014
Q4 		$559K Hold
22,261
– – 0.01% 390
2014
Q3 		$692K Hold
22,261
– – 0.01% 371
2014
Q2 		$576K Hold
22,261
– – 0.01% 414
2014
Q1 		$520K Hold
22,261
– – 0.01% 387
2013
Q4 		$565K Hold
22,261
– – 0.01% 316
2013
Q3 		$454K Buy
22,261
+10,780
+94% +$240K 0.01% 350
2013
Q2 		$241K Buy
+11,481
New +$205K 0.01% 368

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geneva Advisors's SGNT Position: Q2 2015 in Review

Geneva Advisors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2015, closing a stake of 22,261 shares — an estimated $518K sold.

Geneva Advisors first reported a position in SGNT in Q2 2013 and held it in 8 quarters. The position peaked at $692K in Q3 2014. 136 funds tracked by Wall St. Rank hold SGNT as of Q2 2015.

  • Geneva Advisors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Geneva Advisors sold 22,261 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2015, an estimated $518K.
  • Geneva Advisors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Geneva Advisors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $692K in Q3 2014.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2015.

Based on Geneva Advisors's 13F filing for Q2 2015, filed 3 Aug 2015.